KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Non-Current Deferred Tax Liability (2016 - 2023)

Inovio Pharmaceuticals' Non-Current Deferred Tax Liability history spans 14 years, with the latest figure at $32046.0 for Q3 2023.

  • On a quarterly basis, Non-Current Deferred Tax Liability changed 0.0% to $32046.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $32046.0, a 0.0% change, with the full-year FY2022 number at $32046.0, changed 0.0% from a year prior.
  • Non-Current Deferred Tax Liability hit $32046.0 in Q3 2023 for Inovio Pharmaceuticals, roughly flat from $32046.0 in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for INO hit a ceiling of $32046.0 in Q4 2019 and a floor of $24766.0 in Q1 2019.
  • Historically, Non-Current Deferred Tax Liability has averaged $31094.7 across 5 years, with a median of $32046.0 in 2019.
  • The widest YoY moves for Non-Current Deferred Tax Liability: up 29.4% in 2019, down 0.0% in 2019.
  • Tracing INO's Non-Current Deferred Tax Liability over 5 years: stood at $32046.0 in 2019, then changed by 0.0% to $32046.0 in 2020, then changed by 0.0% to $32046.0 in 2021, then changed by 0.0% to $32046.0 in 2022, then changed by 0.0% to $32046.0 in 2023.
  • Business Quant data shows Non-Current Deferred Tax Liability for INO at $32046.0 in Q3 2023, $32046.0 in Q2 2023, and $32046.0 in Q1 2023.